Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

PURPOSE: Patients with hormone receptor–negative breast cancer generally do not benefit from endocrine-targeted therapies. However, a subset with androgen receptor (AR) expression is predicted to respond to antiandrogen therapies. This phase II study explored bicalutamide in AR-positive, estrogen re...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Gucalp, Ayca, Tolaney, Sara, Isakoff, Steven J., Ingle, James N., Liu, Minetta C., Carey, Lisa A., Blackwell, Kimberly, Rugo, Hope, Nabell, Lisle, Forero, Andres, Stearns, Vered, Doane, Ashley S., Danso, Michael, Moynahan, Mary Ellen, Momen, Lamia F., Gonzalez, Joseph M., Akhtar, Arooj, Giri, Dilip D., Patil, Sujata, Feigin, Kimberly N., Hudis, Clifford A., Traina, Tiffany A.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2013
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4086643/
https://ncbi.nlm.nih.gov/pubmed/23965901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3327
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים